Screenshot In a recent New York Times article, Gina Kolata explores a striking trend in modern medicine: physicians, particularly in cardiology and endocrinology, are increasingly turning to GLP-1 receptor agonists like Ozempic, Wegovy, and Zepbound—not just for their patients, but for themselves. The piece highlights how these medications, initially designed to manage diabetes, are now being embraced by medical professionals... Continue Reading →